Insider Transactions in Q1 2025 at Atai Life Sciences N.V. (ATAI)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 24
2025
|
Apeiron Investment Group Ltd. |
BUY
Open market or private purchase
|
Indirect |
1,800,000
+4.08%
|
$1,800,000
$1.4 P/Share
|
|
Mar 21
2025
|
Glenn Frank Short Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
13,161
-23.72%
|
$13,161
$1.35 P/Share
|
|
Mar 21
2025
|
Anne Nagengast Johnson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
33,545
-19.32%
|
$33,545
$1.35 P/Share
|
|
Mar 21
2025
|
Srinivas Rao |
SELL
Open market or private sale
|
Direct |
75,418
-26.15%
|
$75,418
$1.35 P/Share
|
|
Mar 21
2025
|
Kevin James Craig Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,563
-57.82%
|
$11,563
$1.35 P/Share
|
|
Mar 21
2025
|
Sahil Kirpekar Chief Business Officer |
SELL
Open market or private sale
|
Direct |
48,563
-29.58%
|
$48,563
$1.35 P/Share
|
|
Mar 14
2025
|
Sahil Kirpekar Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+37.85%
|
-
|
|
Mar 14
2025
|
Srinivas Rao |
BUY
Exercise of conversion of derivative security
|
Direct |
175,000
+37.77%
|
-
|
|
Mar 14
2025
|
Glenn Frank Short Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,500
+36.93%
|
-
|
|
Mar 14
2025
|
Kevin James Craig Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
-
|
|
Mar 14
2025
|
Anne Nagengast Johnson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100,000
+36.55%
|
-
|
|
Feb 14
2025
|
Apeiron Investment Group Ltd. |
BUY
Open market or private purchase
|
Indirect |
10,835,718
+21.08%
|
$21,671,436
$2.1 P/Share
|